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To identify the disease-causing gene responsible for an autosomal dominantly inherited Charcot–Marie–Tooth neuropathy
subtype in a family excluded for mutations in the common Charcot–Marie–Tooth genes, we used array-based sequence capture
to simultaneously analyse the disease-linked protein coding exome at chromosome 14q32. A missense mutation in fibulin-5,
encoding a widely expressed constituent of the extracellular matrix that has an essential role in elastic fibre assembly and has
been shown to cause cutis laxa, was detected as the only novel non-synonymous sequence variant within the disease interval.
Screening of 112 index probands with unclassified Charcot–Marie–Tooth neuropathies detected two further fibulin-5 missense
mutations in two families with Charcot–Marie–Tooth disease and hyperextensible skin. Since fibulin-5 mutations have been
described in patients with age-related macular degeneration, an additional 300 probands with exudative age-related macular
degeneration were included in this study. Two further fibulin-5 missense mutations were identified in six patients. A mild to
severe peripheral neuropathy was detected in the majority of patients with age-related macular degeneration carrying mutations
in fibulin-5. This study identifies fibulin-5 as a gene involved in Charcot–Marie–Tooth neuropathies and reveals heterozygous
fibulin-5 mutations in 2% of our patients with age-related macular degeneration. Furthermore, it adumbrates a new syndrome
by linking concurrent pathologic alterations affecting peripheral nerves, eyes and skin to mutations in the fibulin-5 gene.
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Introduction
Fibulin-5 (FBLN5) is an extracellular matrix calcium-binding glyco-
protein expressed in elastic fibre-rich tissues (Yanagisawa et al.,
2009). It is critical for correct deposition of elastin, mediates
cell-matrix communication and regulates organogenesis, fibrogen-
esis, vascular remodelling and tumour metastasis (Zheng et al.,
2007; Yanagisawa et al., 2009). Three homozygous missense
mutations (p.C217R, p.S227P and p.R284X) in FBLN5 have
been reported in patients with an autosomal recessive, generalized
form of the connective tissue disorder cutis laxa (Loeys et al.,
2002; Elahi et al., 2006; Hu et al., 2006; Claus et al., 2008;
Nascimento et al., 2010), and a heterozygous in-frame tandem
duplication of exons 5–8 in FBLN5 was seen in a sporadic patient
with cutis laxa suggesting that the large protein acts in a dominant
negative way (Markova et al., 2003). Ten distinct, heterozygous
FBLN5 missense mutations have been associated with age-related
macular degeneration, the leading cause of severe visual loss
among patients older than 50 years in the western world (Stone
et al., 2004; Lotery et al., 2006; Jones et al., 2009, 2010;
Schneider et al., 2010). The p.S227P, the p.C217R FBLN5 mutants
causing cutis laxa, and the age-related macular degeneration-
associated p.G412E, p.G267S, p.I169T and p.Q124P FBLN5 mutants
showed decreased secretion suggesting compromised elastic fibre
formation as a likely mechanism of the disease (Lotery, 2006;
Jones, 2010). In eyes with age-related macular degeneration
FBLN5 has been localized to pathologic basal deposits beneath
the retinal pigment epithelium as well as in some small drusen
(Mullins et al., 2007). The molecular interactions of FBLN5 and
the biochemical basis underlying pathogenic effects of FBLN5
alterations still remain incompletely understood (Zheng et al.,
2007; Jones et al., 2009, 2010; Schneider et al., 2010).
The inherited peripheral neuropathies, also known as Charcot–
Marie–Tooth disease, comprise a clinically and genetically heteroge-
neous group of neuromuscular disorders characterized by lifelong
disability due to distal muscle weakness and sensory disturbances
in upper and lower limbs. Diverse molecular pathways involved in
the pathogenesis of Charcot–Marie–Tooth disease have been elu-
cidated in the past and mutations in 430 genes have been iden-
tified (Reilly and Shy, 2009). It has also been speculated that
extracellular matrix genes might be good candidates for
Charcot–Marie–Tooth neuropathies as interactions between
Schwann cells and extracellular matrix are required for myelin-
ation in the developing peripheral nervous system (Berti et al.,
2006).
To identify the causative gene responsible for an autosomal
dominant Charcot–Marie–Tooth disease subtype 1, we mapped
the disease locus to chromosome 14q32 by single nucleotide poly-
morphism array-based linkage analysis, and applied sequence cap-
ture array-based resequencing to simultaneously analyse all
protein encoding genes within the disease interval. A novel mis-
sense mutation in FBLN5 was detected and subsequently two
further FBLN5 mutations were identified in families with
Charcot–Marie–Tooth disease. In each Charcot–Marie–Tooth dis-
ease family one patient was also diagnosed with age-related
macular degeneration, and four patients had hyperelastic skin.
Based on these findings we expanded our study to examine a fur-
ther 300 patients with exudative age-related macular degeneration
to delineate the characteristics of a novel oculo-neuro-cutaneous
syndrome caused by mutations in FBLN5.
Materials and methods
Study participants
A total of 424 patients were enrolled in this study. One hundred and
twenty-four probands (including all index patients and additional af-
fected family members) had genetically unclassified Charcot–Marie–
Tooth disease and 300 patients were diagnosed with exudative
age-related macular degeneration. In addition, direct sequencing was
performed in 317 healthy control subjects, 85 of which—all being
450 years—were excluded for age-related macular degeneration by
ophthalmological examination. The particular c.268 G4A FBLN5 vari-
ant (encoding p.G90S FBLN5) was tested in 200 additional healthy
control individuals.
Study participants were ascertained at the Medical University of
Graz, Austria and gave written informed consent. The study was
approved by the local Ethical Committee of the Medical University
of Graz.
Clinical, electrophysiological and
ophthalmological evaluation
After obtaining medical and family history, a full neurological examin-
ation was carried out by an experienced neurologist (M.A.-G.) in all
patients with Charcot–Marie–Tooth disease, healthy relatives and in
age-related macular degeneration probands carrying FBLN5 mutations.
Electrophysiological studies followed standard methods. Motor nerve
conduction velocities were used for further subclassification of the
patients with Charcot–Marie–Tooth disease: a cut-off of 38 m/s for
the median motor nerve conduction velocity established a diagnosis
of Charcot–Marie–Tooth disease type 1 (538 m/s, demyelinating
Charcot–Marie–Tooth disease subtype), or Charcot–Marie–Tooth dis-
ease type 2 (438 m/s, axonal Charcot–Marie–Tooth disease subtype).
Patients lacking sensory disturbances both clinically and electrophysio-
logically were classified as spinal Charcot–Marie–Tooth disease (also
known as distal hereditary motor neuropathy) (Reilly and Shy,
2009). Based on these criteria, 63 patients with Charcot–Marie–
Tooth disease were diagnosed as Charcot–Marie–Tooth disease type
1, 38 as Charcot–Marie–Tooth disease type 2 and 23 as spinal
Charcot–Marie–Tooth disease. Electromyography was performed in
selected patients only.
Patients with age-related macular degeneration and Charcot–Marie–
Tooth disease probands carrying FBLN5 mutations received an opthal-
mological examination by experienced opthalmologists (M.W., A.H.)
including visual acuity testing, slit lamp and fundus examination.
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Also, optical coherence tomography and fluorescein angiography were
performed in most patients.
Molecular genetic studies
Linkage studies
DNA was isolated from peripheral blood samples according to standard
methods. Initially, genetic linkage studies were performed in two
families (Families A and B, Fig. 1) whose ancestors originated from
the same small village but in whom blood relationship could not be
established by genealogical studies. Index patients of both families
were excluded for mutations in PMP22, MPZ, GJB1, LITAF, EGR2
and NEFL. In Family A GDAP1 also tested negative. Samples from
eight affected, three unaffected individuals and two spouses from
Families A and B were hybridized to Affymetrix GeneChip Human
Mapping 10 K arrays XbaI 142 2.0 (Affymetrix). For fine mapping of
the locus, five of these affected individuals were subsequently geno-
typed using the Affymetrix Human SNP Array 6.0. Parametric
multipoint log of odds score calculations and haplotypes were obtained
with the ALLEGRO program (Gudbjartsson et al., 2005) and an
autosomal-dominant, fully penetrant model.
Sequence capture array design
A custom tiling 385 K sequence capture array targeting the exonic
sequences of all protein-encoding genes (a total of 120.4 kb) within
chromosome 14: bp 87 435 655–91 913 433 was designed using
BioMart EnsEMBL release 54—May 2009 based on the NCBI 36 as-
sembly of the human genome (November 2005) and manufactured by
Roche NimbleGen. Sequence Capture followed the manufacturer’s in-
structions (Roche NimbleGen). A GFF- or BED-formatted file allowing
visualization of the tiled intervals by the Genome Browser (http://
genome.ucsc.edu/) is available on request.
Sequence capture library construction
Genomic DNA (20mg) from Patient A16 was processed into a GS FLX
Titanium chemistry compatible capture library according to the
NimbleGen Arrays User’s Guide v.3.0, December 2008 (Roche
NimbleGen, Inc.).
Capture array handling
Hybridization was performed using microarrays merged with X1 mixer
on the NimbleGen Hybridization System for 3 days at 42C follow-
ing the manufacturer’s recommended conditions (NimbleGen
Arrays User’s Guide vs.3.0, Dec. 2008; Roche NimbleGen, Inc.).
Quantitative polymerase chain reaction (SYBR-Green based; LC480
instrument) using four internal NimbleGen control loci (NSC-0237,
NSC-0247, NSC-0268 and NSC-0272) was performed to estimate
relative fold-enrichment (data not shown).
GS FLX sequencing
The amplified capture libraries (4 mg per sample) were processed into
sequencing libraries for the 454 GS-FLX using the GS FLX Titanium
General Library Preparation protocol (454 Life Sciences) according to
the manufacturer’s recommended conditions (without the nebulization
step). The captured sample library was sequenced using a quarter of a
Titanium PicoTiterplate (70  75) run on the GS-FLX platform using
Titanium chemistry and standard settings.
Data analysis: variant detection and
annotation
High confidence differences were calculated using the GS Reference
Mapper software (version 2.3; Roche Diagnostics, 454 Life Sciences)
and USCS genome annotation database for the March 2006 Genbank
freeze assembled by NCBI (hg18, build 36.1) as reference sequence.
The GS Reference Mapper application uses a combination of flow
signal information, quality score information and difference type infor-
mation to determine if a difference is high confidence (GS Reference
Mapper Manual version 2.3; Roche Diagnostics, 454 Life Sciences).
Mutation confirmation
The FBLN5 coding region and splice sites were polymerase chain
reaction-amplified using 11 primer pairs that were designed based
on National Centre for Biotechnology Information annotations for
Figure 1 Simplified and virtual pedigree, as used for the linkage
study, including Families A and B. The gender of the family
members is not shown for privacy. Filled and crossed out
symbols indicate affected and deceased persons, respectively.
Individuals denominated with a ‘B’ have been added to the
pedigree for linkage studies, because they exhibit the same
phenotype as individuals of Family A, are excluded for mutations
in the known Charcot-Marie-Tooth disease type 1 genes, and
originate from the same small village. For linkage analyses,
samples from Patients B5, B9, A11, A14, A15, A16, A17, A18,
A19, A20, A21, A22 and A23 were genotyped using the
Affymetrix GeneChip Human Mapping 10K XbaI 142 2.0
array. Individuals B5, B9, A11, A17 and A23 were later
genotyped using the high-density Affymetrix GeneChip
Human Mapping 6.0 array for high-resolution confirmation
of a common haplotype in Families A and B and fine mapping
of the candidate region.
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FBLN5 genomic reference (NC_000014.8) and messenger RNA
(NM_006329.3) sequences (www.ncbi.nlm.nih.gov, Supplementary
Table 1) and sequenced on an ABI 3730 DNA sequencer.
Skin, muscle and nerve biopsies
Biopsies of sun-protected skin were taken from Patients C1, C2, C3
and B9 and from a healthy control. Tissues from muscle and nerve
biopsies were available from routine diagnostic studies in Patients C1,
C2 and B5. Immunohistochemical detection of FBLN5 and elastin fol-
lowed standard protocols (Kadoya et al., 2005).
Sections from paraffin embedded material were cut, de-paraffinized
and rehydrated. Four antigen retrieval sections were incubated with
proteinase K (Dako REAL
TM
diluted 1:40 with Dako REAL
TM
proteinase
K diluent) for 30 min at room temperature. Subsequently, endogenous
peroxidase activity was blocked by immersion of the sections in 1%
H2O2 in methanol. Staining for elastin was performed according to the
protocol of the UltraVison LP Large Volume Detection System
(Thermo Scientific) starting with Ultra V Block for 5 min at room tem-
perature, incubation with anti-elastin (rabbit, 1:3000, Sigma-Aldrich),
antibody for 30 min at room temperature FBLN5 was detected with
mouse monoclonal (1G6A4) antibody (1:500, Abcam), followed by
incubation with primary antibody enhancer for 10 min at room tem-
perature, horseradish peroxidase polymer for 30 min at room tempera-
ture and detection with liquid DAB + Substrate Chromogen System for
Autostainer (Dako Diagnostica) for 5 min at room temperature.
Sections were counterstained with hemalaun. Between all incubation
steps sections were rinsed three times in phosphate-buffered saline.
Sections were dehydrated and mounted in Tissue Tek Mounting
Media 4494 Coverslipping Resin (Sanova). For negative controls
rabbit IgG (1:3000, Linaris) was used instead of the primary antibody.
Ultrathin sections were counterstained with lead citrate and uranyl
acetate and examined in a Philips EM 10 electron microscope.
Results
Clinical, electrophysiological and
molecular genetic studies
Clinical and electrophysiological findings in eight patients of
Families A and B were consistent with late-onset Charcot–Marie–
Tooth disease type 1 (Table 1, Supplementary Table 2). The oldest
Charcot–Marie–Tooth disease patient in Family A (Patient A11)
had received a diagnosis of age-related macular degeneration at
80 years of age.
Whole genome, multipoint linkage analysis including six af-
fected and three unaffected family members as well as two
spouses of Family A revealed two chromosomal intervals on
chromosomes 3 p and 14q tentatively linked to the disease, with
maximal log of odds scores of 2.1032 and 2.1071, respectively
(data not shown). However, calculation of the enlarged virtual
pedigree including Families A and B with probable relationship
(Fig. 1) revealed a significant maximum log of odds score of
3.31 on chromosome 14q32 only (Fig. 2) with all affected indi-
viduals of Families A and B sharing a haplotype consisting of 17
single-nucleotide polymorphism alleles over a region of 5.9 Mb
(bp 87 435 655–93 339 833). Subsequent genotyping of five pa-
tients (Patients A11, A17, A23, B5, B9) with high density 6.0
Affymetrix arrays confirmed a common haplotype between
Families A and B containing 1534 single nucleotide polymorphism
markers and covering a refined region of 4.5 Mb (bp 87 435 655–
91 913 433). After exclusion of pathogenic mutations in four can-
didate genes selected on putative function and expression profile
(CALM1, GALC, PTPN21, KCNK13) by direct sequencing we
simultaneously analysed all 35 protein coding genes within the
disease region using array-based sequence capture followed by
parallel resequencing (DNA obtained from Patient A16). We gen-
erated 72.2 Mb of sequence information with a 410-fold
sequence coverage for 491% of the coding nucleotides and
exon–intron boundaries within the disease-linked target interval
(Supplementary Table 3, Supplementary Fig. 1). Applying high-
confidence sequence variant filtering using the standard GS
Reference Mapper tool (reference: UCSC genome annotation
database for the March 2006 GenBank freeze assembled by
NCBI hg18 build 36.1, dbSNP build130) identified 12
non-synonymous sequence variants, 11 of which were known
single-nucleotide polymorphisms. A single novel missense variant
was located in exon 10 of FBLN5, segregated with the disease and
causes an exchange of arginine at position 373 to cysteine
(c.1117 C4T, p.R373C; Fig. 3 and Supplementary Fig. 2). The
R373 residue is highly conserved throughout evolution
(Supplementary Fig. 3) and was absent in 317 control individuals
making causality of the disease likely.
To investigate the prevalence of FBLN5 mutations as a potential
cause of Charcot–Marie–Tooth disease neuropathies, we screened
112 further index probands with genetically unclassified Charcot–
Marie–Tooth disease and identified two further sequence vari-
ations. Patient C1 carried a c.268 G4A change (p.G90S) in
exon 4 (Fig. 3), affecting a well, although not fully conserved
residue (Supplementary Fig. 3). This sequence change was not
detected in our 517 healthy control individuals, and was not
reported in previous studies including 1204 patients with
age-related macular degeneration and 766 control individuals
(Stone et al., 2004; Lotery et al., 2006) or in the 1000 genome
project (www.1000genomes.org/). Patient C1 and his brother
who also carried the same c.268 G4A FBLN5 mutation (Patient
C2) exhibited a spinal Charcot–Marie–Tooth disease phenotype
with slowly progressive distal muscle weakness and wasting pre-
dominating in the lower limbs from early childhood (Fig. 4A).
Nerve conduction velocities revealed a pure axonal motor neur-
opathy (Supplementary Table 2). EMG and muscle biopsy were
consistent with chronic neurogenic disturbances. Sural nerve
biopsy was normal. Known pathogenic mutations in several
Charcot–Marie–Tooth disease genes (PMP22, MPZ, GJB1, NEFL,
LITAF, GDAP1, YARS, HSPB1, HSPB8, TRPV4, KIAA1985, exons
13–16 of DNM2, BSCL2, GARS, MFN2) and also in ATP7A, which
is known to cause both X-linked cutis laxa and spinal Charcot–
Marie–Tooth disease (Kennerson et al., 2010), had been excluded
previously in either Patient C1 or C2 by direct sequencing. A novel
sequence variation was identified in YARS (c.1015 G4A;
p.A339T) in Patients C2 and C3 but not in the severely affected
Patient C1. Reported polymorphisms leading to amino acid
changes were detected in LITAF (rs4280262), GARS
(rs1049402), MFN2 (rs41278630; Lawson et al., 2005) and in
ATP7A (rs4826245). Both Patients C1 and C2 demonstrated
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Table 1 Clinical and electrophysiological characteristics of probands carrying FBLN5 mutations
Family/
Individual
number
Age at
disease
onset/
Clinical
presentation
(years)
FBLN5
sequence
variation
Initial
diagnosis
Distal
muscle
involvement
LL/UL
Patellar
tendon
reflexes
Peripheral
neuropathy
LL/ULa
Hyper-
elastic
skin
Distinct
additional
features/
diseases
Age-
related
macular
degeneration
Family A
A11 50/81 p.R373C CMT1 + + + / + + + 1 Yes/Yes No – Yesb
A14 50/64 p.R373C CMT1 + / 2 NE/Yes No CTS-like
symptoms
No
A16 35/47 p.R373C CMT1 + / + + 0 Yes/NE No CTS-like
symptoms
NE
A17 45/55 p.R373C CMT1 + / + 1 Yes/Yes No CTS-like
symptoms
No
A22 AS/30 p.R373C CMT1 / 1 NE/Yes No – No
A23 25/31 p.R373C CMT1 / + 1 Yes/Yes No CTS-like
symptoms
NE
Family B
B5 50/74 p.R373C CMT1 + + + / + + 0 NE/NE No - No
B9 37/43 p.R373C CMT1 + + + / + + + 0 Yes/Yes NE Distal sensory
loss in LL
No
Family C
C1 4/21 p.G90S Spinal CMT + + + / + + 2 Yes/Yes Yes Joint
hypermobilityc
No
C2 4/19 p.G90S Spinal CMT + + + / + + 3 Yes/Yes Yes Joint
hypermobilityc
No
C3 AS/47 p.G90S AS / 1 No/Yes Yes – No
C4 71/73 p.G90S Age-related
macular
degeneration
+ / + + 0 Yes/No No Scoliosis, lordosis Yesd
C5 AS/70 p.G90S AS + / 0 Yes/No No –
Family D No
D1 20/46 p.V126M Spinal CMT + + / + 1 No/Yes Yes Mild scapula
alata
No
D2 82/83 p.V126M AS / 0 Yes/No No Alcohol abuse Yesb
Age-related macular degeneration-Patients
E NE p.V126M Age-related
macular
degeneration
NE NE NE/NE NE NE Yese
F 79/87 p.V126M Age-related
macular
degeneration
/ 2 Yes/NE No Asthma
bronchiale
Yesf
G 79/88 p.G90S Age-related
macular
degeneration
+ + / + 2 Yes/Yes No – Yesf
H 80/85 p.T48I Age-related
macular
degeneration
+ + / + + 0 No/No No – Yesf
K 82/83 p.G267S Age-related
macular
degeneration
NE NE NE/NE NE NE Yesf
L 82/89 p.G267S Age-related
macular
degeneration
/ + 0 Yes/No No – Yesf
Controls
I AS/82 p.V126M Control + + / + 0 Yes/Yes No Distal sensory
loss in LL
No
J AS/84 p.V126M Control / + 0 Yes/No No – No
AS = asymptomatic; CMT1 = Charcot–Marie–Tooth disease type 1; CTS = carpal tunnel syndrome; LL = lower limbs; NE = not examined; UL = upper limbs;
 = not present; + = mild; + + = moderate; + + + = severe; 0 = absent; 1 = diminished; 2 = normal; 3 = brisk.
aFor detailed results and normal values of NCS see Supplementary Table 3.
bBilateral, late, dry.
cFor further features refer to ‘Results’ section.
dBilateral, early, drusen.
eBilateral, late, dry and exudative in right/left eye.
fBilateral late exudative.
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hyperstretchable skin with normal elastic recoil (Fig. 4B). Skin was
not fragile and wound healing was inconspicuous. Additional
features included hypermobility of distal joints, a high palatum,
and mild skeletal abnormalities consisting of pectus excavatus,
prominent chin and dolichocephaly (Fig. 4A, 4B). Growth
retardation had been diagnosed in childhood but the patients
reached a height of 178 and 180 cm as adults. Patient C1 com-
plained of chronic diarrhoea of unknown aetiology and Patient C2
was reported to have limited lung function. Three further family
members (parent C3, grand-aunt C4 and grandparent C5), found
to carry the heterozygous c.268 G4A FBLN5 mutation, were
mildly affected with respect to neurological and/or connective
tissue involvement (Fig. 4C), however Patient C4 was also diag-
nosed with early age-related macular degeneration at age 71
(Table 1, Supplementary Table 2).
A third FBLN5 variation (c.376 G4A; p.V126M; Fig. 3) was
detected in a 46-year-old patient (D1) diagnosed with sporadic
spinal Charcot–Marie–Tooth disease, who had initially been
excluded for mutations in GARS, exon 3 of BSCL2, HSPB1 and
HSPB8. Examination revealed atrophy of the small hand and foot
muscles and hyperstretchable skin (Fig. 4C) but no macular
degeneration. The mutation was inherited from the 83-year-old
father (Patient D2) who had progressive visual loss due to dry
age-related macular degeneration and bilateral cataracts (Fig. 5),
and an axonal neuropathy. The p.V126M FBLN5 variant is highly
conserved (Supplementary Fig. 3) but was also found in three of
our 317 control individuals, in one patient with Charcot–Marie–
Tooth disease type 1 where segregation with the disease in the
family was excluded, and in 2 of 300 patients with age-related
macular degeneration. Re-examination of three of these
individuals revealed normal clinical and mildly abnormal electro-
physiological results in Patient F with age-related macular degen-
eration, whereas Controls I and J presented with marked axonal
neuropathy without age-related macular degeneration at age 82
and 84 years, respectively (Table 1, Supplementary Table 2).
Four further FBLN5 missense variants were detected in the 300
patients with age-related macular degeneration. Proband G with
exudative age-related macular degeneration from age 79 carried
the c.268 G4A (p.G90S) FBLN5 mutation and had mild to mod-
erate weakness and wasting in the small hand and foot muscles
and an axonal neuropathy in upper and lower limbs (Table 1,
Supplementary Table 2). Other causes of peripheral neuropathies
were not known. There was no family history of age-related
macular degeneration or Charcot-Marie-Tooth disease but the pa-
tient had neither sibs nor children. At the FBLN5 locus Patient G
shares 71 single nucleotide polymorphism markers with Patients
C1 and C2 along 1.23 Mb making a common founder of this
mutation conceivable.
Proband H with exudative age-related macular degeneration
carried the novel highly-conserved c.143 C4T (p.T48I) FBLN5
variant (Fig. 3 and Supplementary Fig. 3) that was also absent
in controls. She presented with moderate atrophy in the small
hand muscles and severe gait disturbance that was attributed to
joint degeneration. Nerve conduction velocities were within the
normal range (Table 1, Supplementary Table 2). The deceased
father had had visual loss since age 60 and severe deformity of
the hands by history. The patient had no children.
Further physical examination of Patient K with exudative
age-related macular degeneration carrying the known, highly con-
served p.G267S FBLN5 variant (c.799 G4A) was not possible
Figure 2 Mapping a Charcot–Marie–Tooth disease type 1 locus in Families A and B. The graph represents a parametric log of odds score
(LOD) on the y-axis in relation to genetic position on the x-axis. Human chromosomes are concatenated from p-ter (left) to q-ter (right)
on the x-axis, and the genetic distance is given in centimorgans (cM). This scan identified a single region on chromosome 14q32
segregating with the disease based on the hypothesis of autosomal dominant inheritance and 100% penetrance of the mutation.
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because the patient was already deceased at the time of genetic
diagnosis, whereas neurological examination in Patient L carrying
the same variant revealed a pronounced axonal neuropathy in the
lower limbs (Table 1, Supplementary Table 2).
All known FBLN5 mutations, their frequencies and associated
phenotypes are compiled in Table 2. All FBLN5 sequence variants
identified in this study were additionally reviewed for their exist-
ence in the full project single nucleotide polymorphism call release
data from the 1000 Genomes project (www.1000genomes.org/)
November 2010 Data Release. These single nucleotide polymorph-
ism calls are based on 628 individuals from the 20100804 se-
quence and alignment release of the project. The c.376 G4A;
FBLN5 variant (rs61734479 dbSNP; p.V126M) was the only
known variant cited in this data set.
Skin, muscle and nerve biopsies
In the healthy skin, FBLN5 staining showed fibres of small calibre
in the upper dermis (Fig. 6Aa). In the dermis of Patients C1 and
C2 (data not shown) carrying the p.G90S FBLN5 variant a marked
increase in FBLN5 immunoreactivity was apparent, particularly
recognized as short plump fibres. Immunoreactive fibres were
more pronounced in the lower dermis (Fig. 6Ae). In Patient B9
carrying the p.R373C and in Proband C3 with the p.G90S FBLN5
variant, no prominent changes in the structure of the fibres were
evident (Fig. 6Ac, g).
In the healthy skin, elastic fibres stained by anti-elastin antibody
formed long predominantly horizontal fibres. Below the epidermis
a reticular pattern with candelabra-like structures in the papillae
Figure 3 Mutation detection by direct sequencing. Electropherograms derived from FBLN5 sequencing of exons 4, 8 and 10 from
patients compared to unaffected individuals (wild-type). The positions of the heterozygous mutations are indicated with an arrow above
the sequence. The effect of the mutation is shown to the right of each sequence.
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was observed (Fig. 6Ab). In Patients C1 and C2 (data not shown)
staining was generally absent in the papillary dermis and reduced
in the lower dermis (Fig. 6Af). In all patients, especially in Patients
C1 and C2, elastin-immunoreactive fibres were fragmented and
short. In Probands B9 and C3 only mild changes in structure and
arrangement of these fibres were observed (Fig. 6Ad, h).
Ultrathin skin biopsy sections of Patients C1 and C2 showed
that elastic fibres were reduced in number, small in size and dis-
orderly shaped. Elastotubules were prominent and appeared to be
detached from the elastin. (Fig. 6B, C1a and C2a). Collagen fibres
contained small fibrils (Fig. 6B and C1a, b) and showed some
twisted, rope like arrangement (Fig. 6B and C1b). Isolated collagen
fibrils revealed bending (Fig. 6B and C2b), and cross-banding was
preserved. In Patient C3 number and size of elastic fibres seemed
to be within normal range, but still they were moderately disorder-
ly shaped and elastotubules were prominent (Fig. 6B and C3).
In Patient B9 number and size of elastic fibres seemed to be
within the normal range. They were moderately disorderly shaped
but the structure seemed preserved (Fig. 6B and B9). Dermal-
epidermal junction, papillary dermis and ground structure
appeared normal in all patients (data not shown).
In nerve and muscle biopsies from Patients B5, C1 and C2 no
obvious changes in the immunohistochemical staining patterns for
FBLN5 and elastin were noted (data not shown).
Discussion
We ascertained a novel disease-linked region for a Charcot–
Marie–Tooth disease type 1 neuropathy and identified mutations
in FBLN5 as a likely cause of Charcot–Marie–Tooth disease. This
study is the first demonstrating the concomitant occurrence of
peripheral neuropathy, age-related macular degeneration and
hyperelasticity of the skin based on mutations in FBLN5 and de-
lineates the fundamental clinical characteristics of an independent
Figure 4 Clinical findings. (A) Distal muscle atrophy in the lower limbs and pes cavus foot deformity in Patient C1, and pectus excavatus
in Patient C2, both carrying the p.G90S FBLN5 variant. (B) Hypermobility of joints and hyperextensibility of the skin in Patients C1 and C2
carrying the p.G90S FBLN5 variant. Note also muscle wasting in the small hand muscles. (C) Hyperextensibility of the skin in Proband D1
carrying the p.V126M and in Patient C3 carrying the p.G90S FBLN5 sequence variant.
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hitherto unknown syndrome displaying wide interindividual
variability, even within families.
The power of next-generation sequencing to achieve an accur-
ate genetic diagnosis has been demonstrated (Hodges et al., 2007;
Ng et al., 2010; Nikopoulos et al., 2010). In a patient with
Charcot–Marie–Tooth disease, whole-genome sequencing enabled
the identification of the genetic subtype, but the same study
pointed out considerable limitations addressing the interpretation
of the numerous variants detected in the genome (Lupski et al.,
2010). Furthermore, diagnostic implications of such comprehen-
sive, complete or exome-wide genetic analyses for genetic coun-
selling must be carefully appraised. Our study emphasizes
disease-linked protein coding exome sequencing in families for
which ‘restricted’ loci can be defined as an attractive, rapid and
economic alternative.
During this screen, we gained at least 5-fold high quality cover-
age of 495% of the disease-linked targeted sequence making it
less likely that another disease-causing variant located within the re-
sidual 5% of the target region was missed. As for the majority of
previous linkage studies, functional variants located within the non-
exonic sequences within the disease-linked interval would not have
been detected by using this targeted exon sequencing approach.
We identified five different heterozygous missense mutations in
FBLN5, three of which are novel. Each mutation was associated
with age-related macular degeneration in at least one proband,
each being 470 years. In a cohort of 300 patients with age-
related macular degeneration, 2% (6/300) carried FBLN5 muta-
tions. Opthalmoscopic changes consisted of both early and late
(exudative or dry) age-related macular degeneration. FBLN5 is a
secreted extracellular matrix protein and consists of six calcium-
binding epidermal growth factor-like modules and a FBLN-type
C-terminus (Fig. 7). Mutations located in the first epidermal growth
factor domain appeared to be associated with a spinal Charcot–
Marie–Tooth disease phenotype whereas patients carrying the
p.R373C FBLN5 variant located in the FBLN-type C-terminus
domain presented with a demyelinating neuropathy in upper and
lower limbs. Presently, we cannot explain how distinct FBLN5
mutations may cause different neuropathic phenotypes.
However, this situation is reminiscent of other Charcot–Marie–
Tooth disease genes. Mutations in the MPZ gene may result in
both severe early onset Charcot–Marie–Tooth disease type 1 and
very late onset axonal Charcot–Marie–Tooth disease. Moreover,
associated features such as pupillary abnormalities or deafness
have been described for particular MPZ mutations (De Jonghe
et al., 1999; Shy et al., 2004; Kabzinska et al., 2007). Similarly,
allelic mutations in HSPB1, HSPB8 or BSCL2 have been associated
with Charcot–Marie–Tooth disease type 2, distal hereditary motor
neuropathy or hereditary spastic paraplegia (Evgrafov et al., 2004;
Irobi et al., 2004, Auer-Grumbach et al., 2005; Tang et al., 2005),
and allelic ATL1 mutations cause hereditary sensory neuropathy
type I and hereditary spastic paraplegia (Guelly et al., 2011).
An even more complex spectrum of phenotypes affecting diverse
Table 2 Frequency of known and novel sequence variations in FBLN5 identified in this study compared to the literature
Number of individuals
screened for mutations
in FBLN5
p.T48I p.G90S p.V126M p.R373C p.G267S
Controls This study 317 0 0a 3 0 0b
Stone et al., 2004 429 0 0 0 0 0
Lotery et al., 2006 337 0 0 5 0 0
Patients with initial diagnosis of
age-related macular degeneration
This study 300 1 2 3 0 2
Stone et al., 2004 402 0 0 0 0 0
Lotery et al., 2006 802 0 0 1 0 1
Patients with initial diagnosis of
neuropathyc
This study 124 0 4 2 8 0
Stone et al., 2004 NE NE NE NE NE NE
Lotery et al., 2006 NE NE NE NE NE NE
Total 2711 1 6 14 8 3
aAt this position 200 additional control individuals were tested.
bDuring this study no control samples were tested at this position.
cThree patients carrying the p.G90S FBLN5 variant and one patient carrying the p.V126M FBLN5 variant had hyperextensible skin.
NE = not examined.
Figure 5 Age-related macular degeneration. The left eye of
Patient F carrying the p.V126M FBLN5 sequence variant shows
subretinal fibrosis caused by a choroidal neovascularization due
to age-related macular degeneration (exudative).
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tissues has been reported for allelic mutations in TRPV4, LMNA,
ATP7A or DMN2 (Rankin and Ellard, 2006; Auer-Grumbach et al.,
2010; Durieux et al., 2010; Kennerson et al., 2010). Finally, mu-
tations in the GDAP1, HSPB1 and MFN2 genes have been shown
to cause both autosomal dominant and autosomal recessive
Charcot–Marie–Tooth disease (Houlden et al., 2008; Nicholson
et al., 2008; Crimella et al., 2010). It currently remains unclear
whether the carrier parents of children with cutis laxa due to homo-
zygous FBLN5 mutations are prone to develop any of the features of
our patients described here. Alternatively, the cutis laxa-related
Figure 6 Skin biopsies. (A) Immunhistochemical detection of FBLN5 (red) and elastin (brown) in skin samples from a healthy individual (a,
b), Probands C3 (c, d) and C1 (e, f) carrying the p.G90S FBLN5 mutation and Patient B9 carrying the p.R373C FBLN5 mutation (g, h).
Fibulin-immunoreactive fibres in the upper dermis of the healthy control are thin (a, arrowhead). In the patient carrying the p.G90S FBLN5
mutation these fibres are plump (e, arrowhead). Elastin-immunoreactive fibres in the dermis of the healthy control are long (b, arrowhead)
in contrast to the short and fragmented fibres of the patient carrying the p.G90S FBLN5 mutation (f, arrowhead). Elastin-immunoreactivity
in the dermis of the patients, in general, is much lower than that in healthy dermis and virtually absent in the papillary dermis. Scale
bar = 150 mm (FBLN5), 75 mm (elastin). (B) Electron microscopy of skin samples from the Probands C1, C2 and C3 carrying the p.G90S
FBLN5 mutation and Patient B9 carrying the p.R373C FBLN5 mutation (see text). The arrows shown in C1a and C2a indicate prominent
elastotubules detached from the elastin.
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Figure 6 Continued.
Figure 7 Schematic model of FBLN5 showing epidermal growth factor calcium-binding domains (EGF_Ca) in blue, the low complexity
domain in green (domain boundaries are indicated with amino acid positions above the exons), and the FBLN-type carboxy-terminus (FC)
in yellow; exons 1–11 and disease-associated mutations. Mutations found in patients with cutis laxa or hyperelastic skin are underlined.
Variants found in our probands are indicated in red colour. *Putative polymorphisms.
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FBLN5 mutations might either produce more functional protein than
Charcot–Marie–Tooth disease-associated FBLN5 mutations or do
not interfere with normal elastic fibre assembly from the wild-type
allele.
The most complex although variable phenotype was seen in
patients carrying the p.G90S FBLN5 variant. Predominant distal
motor neuropathy, mild skeletal abnormalities, hyperstretchable
skin and hypermobility of joints indicating some clinical overlap
with Ehlers-Danlos syndrome were striking features in two
sibs with the p.G90S FBLN5 variant. (Savasta et al., 2010).
Interestingly, neuromuscular involvement including axonal neuro-
pathies has also been reported in patients with various types of
Ehlers–Danlos syndrome (Voermans et al., 2009). Though we
cannot completely rule out the possibility that the severe pheno-
type observed in the two youngest patients carrying the p.G90S
FBLN5 variant underlies further disease modifying genes or is
aggravated by an effect of one of the polymorphisms identified
in the Charcot–Marie–Tooth disease genes, it appears unlikely that
this variant is a rare polymorphism considering the fact that it
was not detected in a large number of control subjects. Also,
FBLN5 immunoreactivity, indicating short plump elastic fibres in
these patients, is reminiscent of the recessive form of FBLN5-
associated cutis laxa (Van Maldergem et al., 2009). However, in
contrast to the loss of anti-elastin and reduced FBLN5 immunor-
eactivity as observed for patients with cutis laxa with a homozy-
gous FBLN5 mutation (Hu et al., 2006), we found an increase of
FBLN5 protein staining in our probands carrying heterozygous
FBLN5 mutations (Fig. 6A) with an accumulation of abnormal
elastin in the dermis and a reduction of FBLN5 in the papillary
dermis, but increased FBLN5 deposition in the deep dermis. This
pattern resembles age-related changes in patients with solar elas-
tosis that occur after repeated, prolonged and excessive sun ex-
posure (Kadoya et al., 2005).
Of special interest is the p.V126M FBLN5 variant that was ini-
tially reported as a rare polymorphism (Lotery et al., 2006). Two
later studies however presented controversial data designating this
variant as pathogenic and absent in control individuals (Jones
et al., 2009, 2010). In our study the p.V126M FBLN5 variant was
detected in a proband with distal hereditary motor neuropathy
and in three patients with age-related macular degeneration, but
also in three control individuals, and in a patient with Charcot–
Marie–Tooth disease type 1, in whom segregation with the disease
was excluded, preliminarily suggesting that this variant might be a
rare polymorphism. This is also supported by the data provided
through the 1000 Genomes project (www.1000genomes.org/).
However, five individuals in this study carrying the p.V126M
FBLN5 variant exhibited a disease phenotype of either age-related
macular degeneration, peripheral neuropathy and/or hyperelasticity
of the skin (Table 1, Fig. 4C) pointing to at least increased suscepti-
bility of carriers for any of these diseases. We therefore conclude that
further clinical and genetic studies are needed to make any firm
conclusions concerning the status of this FBLN5 variant.
The important role of FBLN5 in formation and repair of elastic
fibres has been studied extensively and its interactions with fibril-
lin, tropoelastin and lysil oxidase-like proteins have been demon-
strated (Choudhury et al., 2009) (Supplementary Fig. 4). Lysil
oxidase is an extracellular copper enzyme that catalyzes the
covalent cross-link of collagens and elastin, thus being responsible
for stabilization of collagen fibrils and for the integrity and elasti-
city of mature elastin (Rodrı´guez et al., 2008). Altered lysil oxidase
plays a crucial role in X-linked forms of cutis laxa due to ATP7A
mutations and in types of Ehlers–Danlos syndrome (Tu¨mer and
Møller, 2010). Our study identifies novel FBLN5 mutants that
lead to ultrastructural features as in cutis laxa, probably by dis-
turbed interaction with lysil oxidase-like proteins, and also sug-
gests a role of FBLN5 and the extracellular matrix in the
maintenance of the peripheral nervous system.
It has been postulated that variants of FBLN5 identified in pa-
tients with age-related macular degeneration change its biophys-
ical and biochemical properties and consequently cause weakening
of Bruch’s membrane, a thin elastic fibre-enriched membrane that
limits the retinal pigmented epithelium. FBLN5 has also been sup-
posed to act as an endogenous angiogenesis inhibitor, suggesting
that mutations causing a loss of FBLN5 function contribute to the
choroidal neovascularization seen in age-related macular degener-
ation (Sullivan et al., 2007).
It is beyond the scope of this study to elucidate the pathogenic
molecular mechanisms producing the diverse peripheral neur-
opathy phenotypes seen in our patients. Uncovering further pa-
tients with Charcot–Marie–Tooth disease and families carrying
mutations in FBLN5 is needed to confirm its pathogenic role in
the development of peripheral neuropathies. It is conceivable that
the alterations identified in our patients cause misfolding of FBLN5
resulting in decreased secretion and/or impairment of extracellular
matrix protein interactions (Schneider et al., 2010). Failure of
FBLN5 to activate b1 integrin receptors led to cell spreading mi-
gration and proliferation of primary smooth muscle cells (Lomas
et al., 2007). Critical neuronal cell-cell interactions might be dir-
ectly or indirectly damaged by the abnormal matrix composition
thereby leading to typical peripheral neuropathy phenotypes.
According to the reported predominant expression of FBLN5 in
multiple organs like the heart, colon, kidney, lung, pancreas and
placenta, one could expect an even more complex phenotype.
However, overall penetrance with multi-organ involvement might
be modulated by tissue-specific interaction partners and mechan-
isms. The detection of such mechanisms and molecular pathways
will be a challenge of future studies and will once help to develop
reasonable therapies for affected patients.
Web resources and accession
numbers
GenBank: human fibulin-5 cDNA, NM_006329.3, human fibulin-5,
NP_006320.2.
The Human Gene Mutation database: www.hgmd.cf.ac.uk/ac/
index.php.
1000 Genomes database: www.1000genomes.org (Data
Release November 2010).
www.ncbi.nlm.nih.gov.
www.ensembl.org/index.html.
genome.ucsc.edu/.
pfam.sanger.ac.uk.
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